Karim Fizazi, MD, PhD, and Ken Herrmann, MD, MBA, discuss prostate cancer in this IME activity titled "Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not." For the full presentation, please visit us at www.peervoice.com/WJK870.